To explore the diversity of genetic alterations in glioneuronal tumors, a cohort of 26 tumors with pathologic diagnoses that included glioneuronal tumor or ganglioglioma was collected (15 from Massachusetts General Hospital, Boston, 11 from Vancouver General Hospital, Vancouver), and examined for BRAF V600 and IDH1 mutations and oncogenic fusions using targeted next generation sequencing (NGS).7 BRAF V600E and IDH1 R132H mutant protein expression was confirmed by immunohistochemistry. This evidence concerns the gene IDH1 and ganglioglioma.